Originally Broadcast: Wednesday, November 13, 2019
Head and neck cancer that is positive for the human papillomavirus (HPV+) represents a disease with increasing incidence, but better prognosis, compared to non-HPV related disease. This webinar will discuss:
- the pathogenesis and epidemiology of HPV+ head and neck cancer
- the management of HPV+ head and neck cancer
- de-intensification strategies to improve long-term function
- immunotherapy efficacy in HPV+ head and neck cancer
Cost: This webinar is FREE thanks to the generosity of an unrestricted educational grant from Bracco Diagnostics. The National Foundation of Swallowing Disorders is a non-profit organization that relies on the financial support of our sponsors and community members. 100% of donations received by webinar registrants will be directed towards head and neck cancer-related dysphagia research.
No ASHA CEUs will be offered for this webinar.
Meet the Presenter: Ezra Cohen, MD, FRCPSC, FASCO. Ezra Cohen is co‐Director of the San Diego Center for Precision Immunotherapy and an internationally renowned translational researcher. A physician‐scientist, Dr. Cohen led an independently funded laboratory interested in mechanisms of action of novel therapeutics. He has made major contributions to targeted and immunotherapy. His research has received peer‐reviewed funding in the study of epidermal growth factor receptor inhibitors, cell therapy, and immunotherapy in head and neck cancer. He has made major contributions to the understanding of critical signaling pathways, integration of novel agents into standard of care, and definition of mechanisms to overcome resistance to drug therapy. He has also recently co‐developed a personalized neoantigen vaccine using unique cancer mutations to boost an anti‐tumor immune response.
Dr. Cohen is Associate Director for Translational Science and leader of the Solid Tumor Therapeutics research program at Moores Cancer Center. He brings his expertise and preeminent reputation in head and neck cancer research and patient care to solid tumor therapeutics. Among other roles, he is chair of the Protocol Review and Monitoring Committee (PRMC) and serves as a member of the Cancer Council, and the Cancer Center’s Executive Committee.
Dr. Cohen recently served as editor‐in‐chief of Oral Oncology, the highest impact specialty journal in head and neck cancer, and currently serves as senior editor for Clinical Cancer Research. He has been the principal investigator on multiple studies of novel agents in head and neck cancer and other solid tumors in all phases of development including chemo prevention, phase I, II, and III trials. Dr. Cohen has authored more than 170 papers and has presented his research at national and international meetings. In addition, he has served as a grant reviewer for the NIH, American Association for Cancer Research, American Society of Clinical Oncology, and the Ontario Institute for Cancer Research.
Dr. Cohen completed residencies in Family Medicine at the University of Toronto and in Internal Medicine at Albert Einstein College of Medicine. He completed a Hematology/Oncology fellowship at the University of Chicago where he was named chief fellow. Prior to his arrival in San Diego, Dr. Cohen was Co‐Director of the Head and Neck Cancer Program, Associate Director for Education and Program Director for the Hematology/Oncology Fellowship at the University of Chicago Comprehensive Cancer Center. A dedicated educator, Dr. Cohen also mentored and developed young faculty in his program.
Medical disclaimer. This Webinar is for informational purposes only and should not be used as a substitute for consultation with an appropriate health care professional, as each individual’s medical situation is unique. It is important that you consult with your medical professional (e.g., physician, SLP) before implementing any course of treatment. Experiences that are new to you should be done with the help of a caregiver and when access to emergency medical care is available.